# Graves' Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review)

Mathilde Peiffert, Christine Cugnet-Anceau, Stéphane Dalle, Karim Chikh, Souad Assaad, Emmanuel Disse, Gérald Raverot, Françoise Borson-Chazot, Juliette Abeillon-Du Payrat

<figure><img src="image_1.png" /></figure>

► To cite this version:

Mathilde Peiffert, Christine Cugnet-Anceau, Stéphane Dalle, Karim Chikh, Souad Assaad, et al. Graves' Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review). Cancers, 2021, 13 (8), pp.1944. 10.3390/cancers13081944. hal-03299852

HAL Id: hal-03299852

https://hal.inrae.fr/hal-03299852v1

Submitted on 4 Apr 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_2.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
Article

# Graves' Disease during Immune Checkpoint Inhibitor Therapy
(A Case Series and Literature Review)

Mathilde Peiffert <fnref n="1" />,<fnref n="2" />*, Christine Cugnet-Anceau <fnref n="3" />,<fnref n="4" />, Stephane Dalle <fnref n="1" />,<fnref n="4" />,<fnref n="5" />, Karim Chikh <fnref n="1" />,<fnref n="6" />, Souad Assaad <fnref n="7" />,<fnref n="8" />, Emmanuel Disse <fnref n="1" />,<fnref n="3" />,<fnref n="9" />, Gérald Raverot <fnref n="1" />,<fnref n="2" />,<fnref n="10" /> ID, Françoise Borson-Chazot <fnref n="1" />,<fnref n="2" />,† ID and Juliette Abeillon-du Payrat <fnref n="2" />,<fnref n="4" />,*,†

<figure><img src="image_3.png" /></figure>

check for
updates

**Citation:** Peiffert, M.; Cugnet-Anceau, C.; Dalle, S.; Chikh, K.; Assaad, S.; Disse, E.; Raverot, G.; Borson-Chazot, F.; Abeillon-du Payrat, J. Graves' Disease During Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review). *Cancers* **2021**, *13*, 1944. https://doi.org/10.3390/cancers13081944

Academic Editors: Marialuisa Luisa Appetecchia and Giancarlo Troncone

Received: 15 March 2021
Accepted: 14 April 2021
Published: 17 April 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

<figure><img src="image_4.png" /></figure>

**Copyright:** © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

**Simple Summary:** Immune checkpoint inhibitor (ICPi)-induced thyroid dysfunction is a frequent immune-related adverse event (irAE). ICPi-induced thyrotoxicosis is usually the first stage of a biphasic thyroiditis with secondary hypothyroidism, whereas ICPi-induced Graves' disease (GD), due to the stimulating activity of TSH-receptor autoantibodies, is extremely rare. The aim of this study was to describe the characteristics and evolution of GD during ICPi therapy. We showed that in five patients with induced GD, two patients evolved into classical GD and the three other patients evolved as thyroiditis with short-term thyrotoxicosis and secondary long-term hypothyroidism, with the initial scintigraphic appearance seeming to predict their evolution. Three other patients had a diagnosis of GD before ICPi treatment: all evolved towards definitive hypothyroidism during treatment, without the appearance of irAE. None of the eight patients developed severe hyperthyroidism with life-threatening symptoms, nor significant Graves' orbitopathy. Use of ICPis in this population with induced or pre-existing autoimmune GD disease therefore appears to be safe.

**Abstract:** Thyrotoxicosis is an adverse event associated with immune checkpoint inhibitors (ICPis) that occurs in 0.6 to 3.2% of treated patients, depending on ICPi class. Presentation usually consists of a biphasic thyroiditis with transient thyrotoxicosis and secondary hypothyroidism. ICPi-induced Graves' disease (GD), due to the stimulating activity of TSH-receptor autoantibodies (TRAb), is extremely rare. The aim of this retrospective study was to describe the characteristics and evolution of GD during ICPi therapy. Five among 243 patients followed for ICPi-induced thyrotoxicosis showed TRAb positivity (2% of the cohort). GD occurred quickly after initiation of ICPis; its course was typical for two patients, with prolonged requirement for antithyroid drug treatment (ATD). The three other patients experienced biphasic thyroiditis with secondary hypothyroidism requiring long-term substitution. Three other patients had a diagnosis of GD before starting ICPis; they evolved toward hypothyroidism with early cessation of ATD and long-term substitution treatment during ICPi treatment. None developed significant Graves' orbitopathy. ICPi treatment was not interrupted for thyroid dysfunction. In conclusion, GD is a rare, immune-related adverse event of ICPis with an unusual course and frequent evolution to biphasic thyroiditis. In the case of ICPi-induced thyrotoxicosis in the presence of TRAb, observing the spontaneous evolution and performing a

<footnote n="1">¹ Faculté de Médecine, Université Lyon 1, 69008 Lyon, France; stephane.dalle@chu-lyon.fr (S.D.); karim.chikh@chu-lyon.fr (K.C.); emmanuel.disse@chu-lyon.fr (E.D.); gerald.raverot@chu-lyon.fr (G.R.); francoise.borson-chazot@chu-lyon.fr (F.B.-C.)</footnote>

<footnote n="2">² Fédération d'Endocrinologie, Hôpital Louis Pradel, Groupement Hospitalier Est, Hospices Civils de Lyon, 69500 Bron, France</footnote>

<footnote n="3">³ Service d'Endocrinologie-Diabète-Nutrition, Hôpital Lyon Sud, Hospices Civils de Lyon, 69310 Pierre-Bénite, France; christine.cugnet-anceau@chu-lyon.fr</footnote>

<footnote n="4">⁴ ImmuCare, Institut de Cancérologie, Hospices Civils de Lyon, 69002 Lyon, France</footnote>

<footnote n="5">⁵ Service de Dermatologie, Hôpital Lyon Sud, Hospices Civils de Lyon, 69310 Pierre-Bénite, France</footnote>

<footnote n="6">⁶ Centre de Biologie Sud, Hôpital Lyon Sud, Hospices Civils de Lyon, 69310 Pierre-Bénite, France</footnote>

<footnote n="7">⁷ Tox'imm, Centre Léon Bérard, 69008 Lyon, France; souad.assaad@lyon.unicancer.fr</footnote>

<footnote n="8">⁸ Service d'Hématologie et Médecine Interne, Centre Léon Berard, 69008 Lyon, France</footnote>

<footnote n="9">⁹ INSERM U1060, INRA 1397, INSA Lyon, Centre de Recherche en Nutrition Humaine Rhône-Alpes (CRNH RA), CarMeN Laboratory, 69310 Pierre-Bénite, France</footnote>

<footnote n="10">¹⁰ INSERM U1052, CNRS, UMR5286, Cancer Research Center of Lyon, 69008 Lyon, France</footnote>

<footnote>* Correspondence: mathilde.peiffert@chu-lyon.fr (M.P.); juliette.abeillon@chu-lyon.fr (J.A.-d.P.); Tel.: +33-4-27-85-66-66 (J.A.-d.P.)</footnote>

<footnote>† These authors contributed equally to the work.</footnote>
scintigraphy are useful before starting ATD treatment. Pre-existing GD is not exacerbated by ICPis and tends to evolve towards hypothyroidism. ICPi treatment can be maintained with adequate biochemical surveillance.

**Keywords:** Graves' disease; immune checkpoint inhibitors; immune-related adverse event; endocrine toxicities; thyroid dysfunction

# 1. Introduction

Immunotherapies are recent anti-cancer treatments that have been developed over the last fifteen years and which now play a major role in the treatment of several cancers, including melanoma, lung, and kidney. Their mechanism of action is via the reactivation of T lymphocytes through targeting immune checkpoints that are used by cancer cells to cause immunosuppression. Immune checkpoint inhibitors (ICPis) target different immune checkpoints and consist of monoclonal antibodies directed against cytotoxic T-lymphocytic-associated antigen-4 (anti-CTLA-4 antibodies: Ipilimumab, Tremelimumab), programmed cell death 1 protein (anti-PD-1 antibodies: Nivolumab, Pemprotilizumab and Cemiplimab), and programmed cell death ligand-1 (anti-PD-L1 antibodies: Atezolizumab, Durvalumab and Avelumab). Other agents in this class of drugs are also currently under clinical trials. The range of indications for these treatments has been broadening each year [1].

However, by inhibiting negative regulators of adaptive immunity, ICPis may also trigger immune-related adverse events (irAE) involving different organs, with a frequency of 14% of grade 3 and 4 irAE observed with anti-PD-(L)1 treatment, 34% with anti-CTLA-4 treatment, and 55% with combined immunotherapy [2].

The endocrine irAEs involve several endocrine glands (pituitary, thyroid, adrenals, and pancreas) [3]. Anti-CTLA-4 preferentially exhibited pituitary toxicity with hypophysitis (up to 10%), whereas anti-PD-(L)1 more frequently caused thyroid diseases, estimated at 1 to 10%, and up to 50% when subclinical dysthyroidism and systematic screening are included [4–8]. Frequency of frank hypothyroidism is estimated to be 6.6% with ICPis, whereas the reported incidence of hyperthyroidism is lower than that of hypothyroidism (3.2% of patients treated with anti-PD-1, 0.6% with anti-PD-L1 and 1.7% with anti-CTLA-4) [6,9]. The hyperthyroid phase typically evolves into hypothyroidism, which may explain many cases of hyperthyroidism being missed in clinical studies [10].

Thyroid dysfunctions (TDs) generally appear during the first weeks of ICPi treatment, although they may in some cases be delayed [7,11,12]. Pre-existing TD and combined or successive use of ICPis seem to multiply these thyroid side effects by 3–4-fold [4–6,11–13]. Most patients with hypothyroidism treated by Levothyroxine prior to ICPi treatment need to increase their dosage. A few patients with prior hypothyroidism developed hyperthyroidism after the initiation of ICPis [11]. A dose-effect is also suggested by a study that used a high dose of Ipilimumab (10 mg/kg), where 10% of patients developed dysthyroidism [14]. Thus, it is recommended that systematic pre-therapeutic evaluations of endocrine function are carried out, then close monitoring during the first months of treatment [15,16]. ICPi-induced thyrotoxicosis is generally due to destructive thyroiditis, with a first stage of hyperthyroidism which then resolves or evolves into secondary hypothyroidism (50–80%) [17–19].

Graves' disease (GD) is an autoimmune disease (AID) due to the stimulating activity of TSH-receptor autoantibodies (TRAb). Its diagnosis is based on the association of thyrotoxicosis and the presence of TRAb positivity and/or orbitopathy. GD is unusual during ICPi treatment and has so far rarely been described in the literature.

The aim of this study was to describe the profile of thyrotoxicosis in the presence of TRAb in patients undergoing treatment with ICPis.
## 2. Materials and Methods

A descriptive cohort study with longitudinal follow-up was conducted, in the tertiary referral center of the University Hospital of Lyon (Hospices Civils de Lyon), France. Patients included were referred either by dermatologists, respiratory physicians, or oncologists for thyrotoxicosis during ICPi treatment, from December 2015 to December 2020, through the ImmuCare and Tox'imm networks (healthcare networks in Lyon including patients who have presented irAEs due to ICPis during treatment for cancer) [20].

We included adult patients presenting with thyrotoxicosis diagnosed at pre-therapeutic screening or during follow up for ICPi treatment for any cancer, and showing as positive for TRAbs.

The diagnosis of thyrotoxicosis was accepted in the case of low thyroid stimulating hormone (TSH) levels (normal values: 0.4–4 mUI/L) with concomitant high free thyroxine (FT4, normal values: 12–22 pmol/L) and/or high free triiodothyronine (FT3, normal values: 3.1–6.8 pmol/L) (chemiluminescence immunoassay (I2000; Abbott Laboratories, Abbott Park, IL, USA)).

TRAb levels were considered positive if above 1.6 UI/L (electrochemiluminescence, Cobas e411; Roche Diagnostics, Mannheim, Germany). In one case, a TRAb bioassay was performed to determine the stimulating activity. Thyroperoxidase autoantibodies (TPOAb) were considered positive if above 34 UI/mL (electrochemiluminescence immunoassay, Cobas e411; Roche Diagnostics, Mannheim, Germany).

When required, morphological assessment was based on cervical Ultrasound-Doppler examination and functional assessment by 99mTc uptake on thyroid scintigraphy.

Secondary hypothyroidism evolution was diagnosed in the case of high TSH with low FT4/FT3 in the absence of any thyroid treatment.

Patient follow-up was based on clinical examination and biochemical follow-up, the frequency of which was at the discretion of the endocrinologist.

Data were processed anonymously. In accordance with legislation in place at the time of the study, the study was declared to the data protection agency (Commission Nationale Informatique et Liberté; no. 18-297) and an information letter was sent to living patients; written informed consent was not required. The study was also approved by the Ethics Committee of the Hospices Civils de Lyon (no. 19-163.).

## 3. Results

### 3.1. *Patients*

A total of 243 patients (150 male and 93 female) were referred for thyrotoxicosis during ICPi treatment. Five patients developed induced-thyrotoxicosis with positive TRAb (2% of the cohort) and were included in the "ICPi-induced Graves' disease" group. Additionally, three patients had been diagnosed for Graves' disease prior to starting ICPis (TRAb-positive thyrotoxicosis), and these patients were included in the "Pre-therapeutic Graves' disease" group (Figure 1).

### 3.2. *ICPi-Induced Graves' Disease*

Five patients (numbers 1 to 5, Table 1.) were treated with anti-PD-1 monotherapy or with a combination of anti-PD-(L)1 and anti-CTLA4. Patients 4 and 5 were current smokers. None of the patients had a personal history of autoimmune disease nor of thyroid dysfunction; their family histories were unknown. All had normal pre-therapeutic thyroid function, and none had previously received an anti-cancer treatment that induced thyroid adverse events. For four patients, thyrotoxicosis was diagnosed quickly after ICPi initiation, while for patient 1 diagnosis was much later during the maintenance phase. None showed any clinical criteria for severe hyperthyroidism (cardiothyreosis), nor any alteration in general state requiring hospitalization, thanks to systematic biochemical screening of thyroid function. None of these patients developed significant Graves' orbitopathy requiring specific treatment.
<figure><img src="image_5.png" /><figcaption>**Figure 1.** Flow chart. ICPis: immune checkpoint inhibitors; TRAb: TSH-receptor autoantibodies.</figcaption></figure>

For patients 1 and 2, the course of the thyrotoxicosis was typical of a Graves' hyperthyroidism (Figure 2A.): both were treated with an antithyroid drug (ATD) and TSH normalized quickly; TRAb normalization occurred after more than 6 months. Total duration of ATD treatment was about one year for patient 1, with a slow decrease in ATD treatment until spontaneous euthyroidism; patient 2 was still undergoing treatment with ATD after 6 months because early tapering of treatment resulted in early recurrence of hyperthyroidism. Both patients were treated with corticotherapy for an additional grade 3 irAE (for patient 1, subsequent autoimmune hepatitis, and for patient 2, consecutive autoimmune pneumopathy); these irAEs resulted in the withdrawal of ICPis.

<figure><img src="image_6.png" /><figcaption>**Figure 2.** Evolution of thyroid dysfunction. (A) Patient no. 1; (B) Patient no. 3; (C) Patient no. 6. TSH: thyroid stimulating hormone; FT4: free thyroxine; ICPi: immune checkpoint inhibitor; ATD: antithyroid drug therapy; irAE: immune-related adverse event; GC: glucocorticoids; TRAb: TSH-receptor autoantibodies; LVT: levothyroxine.</figcaption></figure>
<table><caption>**Table 1.** ICPi-induced Graves' disease.</caption><thead><tr><th>No.</th><th>Sex<br>Age</th><th>Indication</th><th>ICPi (Name)<br>and Dose</th><th>Cycle/Time<br>Since<br>ICPi<br>Initiation</th><th>Total<br>ICPi<br>Cycles<br>Number</th><th>Other<br>irAE<br>(Time)</th><th>Maximum<br>FT4/FT3<br>(in ULN)</th><th>TRAb<br>at Diag-<br>nosis<br>(in<br>ULN)</th><th>Iodine<br>99mTc<br>Uptake/<br>Hyper-<br>Vascular<br>Doppler</th><th>TPOAb</th><th>ATD<br>(Duration<br>in Weeks)</th><th>Corticosteroids<br>(Time of<br>Introduction)</th><th>Status at Last<br>Follow-Up</th><th>Treatment at<br>Last<br>Follow-Up<br>(Time of<br>Introduction)</th><th>Total<br>Follow-<br>Up<br>(Weeks)</th></tr></thead><tbody><tr><td>1</td><td>F 69</td><td>Serous<br>ovarian<br>carci-<br>noma</td><td>anti-PD-1 (Pem-<br>brolizumab)<br>200 mg/3 weeks<br>anti-CTLA-4<br>and anti-PD-L1</td><td>IX/41<br>weeks</td><td>XIV</td><td>G3<br>(week 15)</td><td>1.3/1.3</td><td>2.7</td><td>High/na</td><td>Negative</td><td>Carbimazole<br>(45)</td><td>Yes *<br>(week 15)</td><td>Euthyroidism</td><td>0</td><td>57</td></tr><tr><td>2</td><td>F 60</td><td>Endometrial<br>adenocar-<br>cinoma</td><td>(Durvalumab<br>and<br>Tremelimumab)<br>1500 mg and<br>76 mg</td><td>1/2 weeks</td><td>I</td><td>G3<br>(week 2)</td><td>2.5/1.8</td><td>5.2</td><td>na/No</td><td>Positive</td><td>Carbimazole<br>(&gt;29 **)</td><td>Yes *<br>(week 2)</td><td>Hyperthyroidism</td><td>Carbimazole<br>1.25 mg/day<br>(week 1)</td><td>30</td></tr><tr><td>3</td><td>M 60</td><td>Small cell<br>bronchial<br>carci-<br>noma</td><td>anti-PD-1 (Pem-<br>brolizumab)<br>200 mg/3 weeks<br>anti-CTLA-4<br>and anti-PD-1</td><td>1/3 weeks</td><td>VI</td><td>No</td><td>3.4/2</td><td>3.5</td><td>na/na</td><td>Positive</td><td>No</td><td>No</td><td>Hypothyroidism</td><td>Levothyroxine<br>150 µg/day<br>(week 17)</td><td>48</td></tr><tr><td>4</td><td>F 44</td><td>Melanoma</td><td>(Ipilimumab<br>and Nivolumab)<br>3 and 1<br>mg/kg/3 weeks<br>anti-PD-1</td><td>1/2 weeks</td><td>II</td><td>G3<br>(week 5)</td><td>1.9/na</td><td>4.1</td><td>Low/No</td><td>na</td><td>No</td><td>No</td><td>DCD ***</td><td>0 ***</td><td>13</td></tr><tr><td>5</td><td>M 76</td><td>Epidermoid<br>lung carci-<br>noma</td><td>(Nivolumab)<br>3 mg/kg/2 weeks</td><td>II/4<br>weeks</td><td>XXXVIII</td><td>No</td><td>2.4/1.3</td><td>48</td><td>na/No</td><td>Negative</td><td>Carbimazole<br>(10)</td><td>No</td><td>Hypothyroidism</td><td>Levothyroxine<br>150 µg/day<br>(week 16)</td><td>143</td></tr></tbody></table>

Time is expressed in weeks, since the beginning of thyrotoxicosis (except where otherwise specified). FT4, FT3 and TRAb are expressed as number of times greater than normal levels. Normal values: FT4 12-22 pmol/L, FT3: 3.1-6.8 pmol/L, TRAb < 1.6 U/L. ICPi: immune checkpoint inhibitor; irAE: immune-related adverse event; FT4: free thyroxine; FT3: free triiodothyronine; ULN: upper limit of normal; TRAb: TSH-receptor autoantibodies; TPOAb: thyroperoxidase autoantibodies; ATD: antithyroid drug therapy; F: female; M: male; anti-PD-1: anti-programmed cell death 1 protein antibodies; anti-PD-L1: anti-programmed cell death ligand-1 antibodies; anti-CTLA-4: anti-cytotoxic T-lymphocytic-associated antigen-4 antibodies; G3: grade 3 of irAE; DCD: deceased; na: not available. * Corticosteroids were prescribed for other irAE; ** Still on ATD; *** Patient 4 died due to cancer evolution before developing frank hypothyroidism, although the last biochemical examination suggested progression to hypothyroidism (loss of TSH suppression, FT3 and FT4 below the lower limit of normal range).
Patients 3, 4 and 5 experienced transient thyrotoxicosis shortly after their first ICPi treatment (Figure 2B). Only patient 5 required ATD, but this was stopped early, and the two others only received symptomatic treatment (beta-blockers). In patients 3 and 5, thyrotoxicosis evolved to hypothyroidism after a few months, requiring long-term substitution of thyroid hormone. Patient 4 died soon after spontaneous evolution towards hypothyroidism (low FT3/FT4 and normalized TSH) one month after the discontinuation of ICPi for a grade 3 irAE (autoimmune hepatitis), without glucocorticoid treatment. No information was available regarding the length of time taken until these patients were negative for TRAbs.

None of these five patients with ICPi-induced GD had treatment interruption due to thyroid dysfunction.

### 3.3. *Pre-Therapeutic Graves' Disease*

Three patients (numbers 6, 7 and 8, Table 2) were diagnosed with GD before starting ICPi treatment; all three received anti-PD-1 (1 Pembrolizumab, 2 Nivolumab).

For patients 6 and 7 (Figure 2C), GD was fortuitously diagnosed with thyrotoxicosis at pre-therapeutic screening (retrospectively in the case of patient 7 whose symptoms evolved over one month; he was also a current smoker). Patient 8 was treated for GD 1.5 years before ICPi treatment; TRAb levels were at the time six-fold greater than the normal upper limit, (ULN) and TPOAb were also positive. The patient was treated with Methimazole for one year until TRAbs tested negative. He was then diagnosed with a renal clear cell carcinoma, firstly treated with a tyrosine-kinase inhibitor (Pazopanib) for one year, with euthyroidism, and then with Nivolumab. GD recurrence was diagnosed during pre-ICPi treatment biochemical examination: TRAbs were higher than the first time, at 14 ULN, with moderate stimulating activity (324%).

All three of these patients were treated with ATD together with ICPis. In all patients, the development of secondary hypothyroidism allowed the early cessation of ATD treatment, whereas TRAbs remained positive. They all required long-term substitution treatment for persistent hypothyroidism, using high doses of Levothyroxine.

None of these patients developed significant Graves' orbitopathy requiring specific treatment, nor developed irAE during ICPi treatment.

## 4. Discussion

ICPi-induced Graves' disease is rare and has been seldom reported in the literature, with only a few case reports published. Although limited, our series is the largest and gives indications on the clinical characteristics and evolution of these patients and the safety of ICPi use in these cases.

GD is an autoimmune pathology, presenting with the association of thyrotoxicosis and TRAb positivity and/or orbitopathy. Functional and morphological examinations typically show high iodine/99mTc uptake on thyroid scintigraphy and a hypervascular pattern on Ultrasound-Doppler. Orbitopathy is associated in almost half of the cases. Specific treatment consists of ATD, usually maintained for one year, allowing a return to spontaneous euthyroidism. Recurrence occurs in 50% of cases, whereas 15% of patients show evolution to secondary hypothyroidism, particularly those that are TPOAb-positive [21–25].

Positive TRAbs were described in 2% of all patients referred for ICPi-induced thyrotoxicosis in our cohort, and this prevalence is probably an overestimate because some patients with mild thyrotoxicosis would certainly not have been referred to an endocrinologist. Patients were treated using different types of ICPi (anti-PD-1, anti-CTLA-4, and a combination of anti-CTLA-4 with anti-PD-(L)1). None had frank orbitopathy that required specific treatment, and no patients were referred for Graves' orbitopathy without thyroxicosis. Thyrotoxicosis symptoms were generally modest, despite high hormone levels, maybe due to their early diagnosis thanks to systematic screening. The majority of induced GD appeared at the beginning of ICPi treatment, but there is a need for the prolonged monitoring of thyroid function because one patient developed GD much later, after 41 weeks of treatment.
<table><caption>Table 2. ICPis pre-therapeutic Graves' disease.</caption><thead><tr><th>No.</th><th>Sex<br>Age</th><th>Indication</th><th>ICPi (Name) and<br>Dose</th><th>Total<br>Number<br>of ICPi<br>Cycles</th><th>TSH/FT4/FT3<br>at Time of<br>ICPi<br>Initiation (in<br>ULN)</th><th>TRAb at<br>GD's Di-<br>agnosis<br>(in ULN)</th><th>TPOAb</th><th>Iodine<br>99mTc<br>Uptake/<br>Hyper-<br>vascular<br>Doppler</th><th>irAE</th><th>ATD<br>Duration<br>(Weeks)</th><th>Time<br>to Nor-<br>malize<br>FT4<br>(Weeks)</th><th>Max<br>TSH/<br>Min FT4<br>(in ULN)<br>and<br>(Time)</th><th>Time to<br>Normal-<br>ize<br>TRAb<br>(Weeks)</th><th>Status at Last<br>Follow-Up</th><th>Treatment at<br>Last<br>Follow-Up<br>(Time of In-<br>troduction)</th><th>Total<br>Follow-<br>Up<br>(Weeks)</th></tr></thead><tbody><tr><td>6</td><td>M 67</td><td>Melanoma</td><td>anti-PD1<br>(Nivolumab)<br>240 mg/2 weeks</td><td>IX</td><td>&lt;0.01/1/1</td><td>2.4</td><td>Negative</td><td>High/Yes</td><td>No</td><td>1</td><td>10</td><td>13/0.1<br>(week 16)</td><td>na**</td><td>Hypothyroidism</td><td>Levothyroxine<br>150 µg/day<br>(week 19)</td><td>34</td></tr><tr><td>7</td><td>M 49</td><td>Bronchial<br>adenocarci-<br>noma</td><td>anti-PD1<br>(Pembrolizumab)<br>200 mg/3 weeks</td><td>IX</td><td>&lt;0.01/3.4/2.5</td><td>1.8</td><td>Positive</td><td>High/Yes</td><td>No</td><td>23</td><td>8</td><td>17/0.5<br>(week 18)</td><td>30</td><td>Hypothyroidism</td><td>Levothyroxine<br>250 µg/day<br>(week 21)</td><td>94</td></tr><tr><td>8</td><td>M 74</td><td>Renal clear<br>cell<br>carcinoma</td><td>anti-PD1<br>(Nivolumab)<br>240 mg/2 weeks</td><td>XIII</td><td>&lt;0.01/1.5/na</td><td>14*</td><td>Positive</td><td>na/Yes</td><td>No</td><td>16</td><td>9</td><td>10/0.6<br>(week 20)</td><td>46</td><td>Hypothyroidism</td><td>Levothyroxine<br>150 µg/day<br>(week 13)</td><td>64</td></tr></tbody></table>

TSH, FT4, FT3 and TRAb are expressed as number of times greater than normal values. Normal values: FT4 12–22 pmol/L, FT3: 3.1–6.8 pmol/L, TSH 0.4–4 mUI/L, TRAb < 1.6 U/L. Time is expressed in weeks since the beginning of thyrotoxicosis (except where otherwise specified). ICPi: immune checkpoint inhibitor; TSH: thyroid stimulating hormone; FT4: free thyroxine; FT3: free triiodothyronine; ULN: upper limit of normal; TRAb: TSH-receptor autoantibodies; GD: Graves' disease; TPOAb: thyroperoxidase autoantibodies; irAE: immune-related adverse event; ATD: antithyroid drug therapy; M: male; F: female; anti-PD-1: anti-programmed cell death 1 protein antibodies; na: not available. * Patient 3 was diagnosed with GD about 1.5 years prior to ICPi treatment, with ATD for one year; he presented with relapse of GD one month before the initiation of ICPi treatment; ** TRAbs were still positive (3,1 ULN) after 12 weeks of thyrotoxicosis evolution; the patient died before further assays were performed.
Usually, the evolution of ICPi-induced thyrotoxicosis presents similar to destructive thyroiditis, with initial hyperthyroidism followed by resolution or evolution towards hypothyroidism in 50–80% of cases [17–19]. Complementary investigations are not useful, except in the case of severe thyrotoxicosis or an unfavorable evolution: TRAb assay, Ultrasound-Doppler, and iodine/99mTc scintigraphy should then be performed to discriminate with differential diagnoses [15]. In typical thyroiditis, thyroid Ultrasound-Doppler shows a heterogeneous hypoechoic parenchyma with low vascularity and low iodine/99mTc uptake on scintigraphy [7]. However, many patients have iterative scans using iodinated contrast agents which can interfere with iodine uptake in scintigraphy. Histological and morphological analysis can demonstrate different pathophysiological mechanisms between autoimmune and ICPi-induced thyrotoxicosis [26,27].

In our series, 75% of patients with GD during ICPi treatment evolved towards hypothyroidism, which is more similar to the evolution of biphasic thyroiditis than that of classical GD. Scintigraphy, when performed, was useful in predicting the evolution, showing high fixation in the case of classical GD, and no fixation in the case of thyroiditis.

Despite the evolution to hypothyroidism, TRAb remained positive for a long period of time. Evolution towards hypothyroidism in some patients could be due to a conversion of TRAbs from stimulating to blocking antibodies, or to a thyroiditis added to Graves' disease; unfortunately, we could not perform TRAb bioassays to conclude. Similar observations were made in Alemtuzumab use for multiple sclerosis in the 1990s: during the reconstitution of autoimmunity, a significant proportion of patients developed GD, with an unusual evolution towards spontaneous euthyroidism or hypothyroidism in 40% of the patients, despite TRAb positivity. [28].

In the literature, initially only induced Graves' orbitopathy (GO) without thyrotoxicosis were described in patients undergoing Ipilimumab (anti-CTLA-4) treatment [29–31]. Polymorphism of CTLA-4 is known to increase the risk of autoimmune susceptibility including Graves' disease, but how it interacts with ICPi is unclear [32–34]. Nevertheless, a small number of more recent case reports have described Graves' disease associated with anti-PD-1 ICPi treatment. The later arrival of their use in oncology could explain this time lag. To the best of our knowledge at the time of writing, only nine cases of ICPi-induced Graves' hyperthyroidism and seven cases of induced Graves' orbitopathy have been described in the literature, associated with anti-PD-1 or anti-CTLA-4 treatment or their combination (Table 3), with only one patient presenting with both thyrotoxicosis and orbitopathy [19,29–31,35–44]. All eight cases of induced GD without orbitopathy showed TRAb positivity and/or high iodine uptake on scintigraphy. These patients were treated using ATD, and only one evolved towards spontaneous hypothyroidism. The only case with an association of induced hyperthyroidism and orbitopathy was reported by Sagiv et al. and was treated with glucocorticoids, and hyperthyroidism resolved spontaneously [42]. In our series, only 40% of induced GD evolved as classical GD would, while 60% showed spontaneous hypothyroidism, highlighting a heterogeneous profile.

Among the six case reports with Graves' orbitopathy but without hyperthyroidism, all were treated with glucocorticoids for eye inflammation, and none presented with thyrotoxicosis nor showed evolution to hypothyroidism (Table 3). Of these six patients only two showed TRAb positivity, and we could reconsider the GO diagnosis in the four others because it may represent ICPi-induced orbitopathy rather than Graves' disease [45].

To the best of our knowledge, there is only one reported case of pre-existing Graves' hyperthyroidism before ICPi treatment [42]. This patient had a history of GD one year before immunotherapy; he commenced Nivolumab in a euthyroid state but experienced a recurrence of thyrotoxicosis with GO that evolved to hypothyroidism, despite persistent positive TRAb. Our three patients with pre-existing GD showed the same course towards hypothyroidism during ICPi treatment, but did not develop GO.
<table><caption>**Table 3.** Review of the literature: case reports of Graves' hyperthyroidism or orbitopathy induced or during ICPi treatment.</caption><thead><tr><th>First Author, Year</th><th>ICPi (Name) and Dose</th><th>Sex Age</th><th>Personal/Familial History of AID or TD</th><th>Hyper-Thyroidism</th><th>GO</th><th>Cycle/Time</th><th>FT4/FT3 (in ULN)</th><th>TRAb (ULN)</th><th>TPOAb</th><th>Iodine 99mTc Up-take</th><th>Doppler US Vascular Pattern</th><th>Other irAE</th><th>Treatment (Duration)</th><th>Hypothyroidism Evolution</th></tr></thead><tbody><tr><td colspan="15">Graves' hyperthyroidism</td></tr><tr><td>De Filette, 2016 [19]</td><td>anti-PD-1 (Pembrolizumab) 2 mg/kg/na</td><td>na</td><td>na/na</td><td>Yes</td><td>No</td><td>na</td><td>na/na</td><td>Positive (na)</td><td>Negative</td><td>na</td><td>na</td><td>na</td><td>No</td><td>Yes</td></tr><tr><td>Azmat, 2016 [35]</td><td>anti-CTLA-4 (Ipilimumab) 3 mg/kg/2 weeks</td><td>M 67</td><td>No/na</td><td>Yes</td><td>No</td><td>II/6 weeks</td><td>2.1/2.2</td><td>Positive (na)</td><td>na</td><td>High</td><td>na</td><td>na</td><td>ATD (na) then Thyroid-ectomy (a)</td><td>Yes (b)</td></tr><tr><td>Gan, 2017 [36]</td><td>anti-CTLA-4 (Tremelimumab) 1 cycle/12-24 weeks</td><td>M 55</td><td>No/No</td><td>Yes</td><td>No</td><td>XX/8 years</td><td>1.6/1.9</td><td>Positive (3.1)</td><td>Positive</td><td>na</td><td>na</td><td>na</td><td>ATD (na)</td><td>No</td></tr><tr><td>Brancatella, 2019 [37]</td><td>anti-PD-1 (Nivolumab) 3 mg/kg/2 weeks</td><td>M 51</td><td>na/na</td><td>Yes</td><td>No</td><td>IV/8 weeks</td><td>1.3/1.6</td><td>Negative</td><td>Negative</td><td>High</td><td>Hyper-vascular</td><td>na</td><td>ATD (na)</td><td>No</td></tr><tr><td>Iadarola, 2019 [39]</td><td>anti-PD-1 (Nivolumab) 3 mg/kg/2 weeks</td><td>F 66</td><td>na/na</td><td>Yes</td><td>No</td><td>II/4 weeks</td><td>1/1.3 (c)</td><td>Negative</td><td>Negative</td><td>High</td><td>Normal</td><td>na</td><td>ATD (na)</td><td>No</td></tr><tr><td>Yajima, 2019 [38]</td><td>anti-PD-1 (Pembrolizumab) 200 mg/3 weeks</td><td>M 61</td><td>No/No</td><td>Yes</td><td>No</td><td>V/14 weeks</td><td>2.3/1.7</td><td>Positive (2.5) (d)</td><td>Negative</td><td>na</td><td>Hyper-vascular</td><td>Colitis</td><td>ATD and GC (&gt;20 weeks) (e)</td><td>No</td></tr><tr><td>Yamada, 2020 [40]</td><td>anti-PD-1 (Nivolumab) 240 mg/3 weeks</td><td>M 66</td><td>No/No</td><td>Yes</td><td>No</td><td>II/6 weeks</td><td>&gt;2.9/2.8</td><td>Positive (15)</td><td>Negative</td><td>High</td><td>Hyper-vascular</td><td>No</td><td>ATD (&gt;18 weeks)</td><td>No</td></tr><tr><td>Kurihara, 2020 [41]</td><td>anti-PD-1 (Nivolumab) 240 mg/2-5 weeks</td><td>M 48</td><td>No/No</td><td>Yes</td><td>No</td><td>VI/16 weeks</td><td>1.1/1.2</td><td>Positive (1.5)</td><td>Negative</td><td>Normal</td><td>Normal</td><td>T1D</td><td>ATD (&gt;64 weeks)</td><td>No</td></tr><tr><td colspan="15">Graves' hyperthyroidism and orbitopathy</td></tr><tr><td>Sagiv, 2019 [42]</td><td>anti-CTLA-4 (Tremelimumab) 10 mg/kg/4 weeks</td><td>M 51</td><td>na/na</td><td>Yes</td><td>Yes</td><td>V/27 weeks</td><td>&gt;1 (na)</td><td>Negative</td><td>Positive</td><td>na</td><td>na</td><td>na</td><td>GC (na)</td><td>No</td></tr><tr><td colspan="15">Graves' orbitopathy</td></tr><tr><td>Borodic, 2011 [31]</td><td>anti-CTLA-4 (Ipilimumab) na</td><td>F 51</td><td>na/na</td><td>No</td><td>Yes</td><td>II/6 weeks</td><td>1/na</td><td>Positive (29)</td><td>Positive</td><td>na</td><td>na</td><td>na</td><td>GC (na)</td><td>No</td></tr><tr><td>Min, 2011 [30]</td><td>anti-CTLA-4 (Ipilimumab) 10 mg/kg/3 weeks</td><td>F 51</td><td>No/na</td><td>No</td><td>Yes</td><td>IV/12 weeks</td><td>1/na</td><td>Positive (1.1) (f)</td><td>Positive</td><td>na</td><td>na</td><td>na</td><td>GC (na)</td><td>No</td></tr><tr><td>McElnea, 2014 [29]</td><td>anti-CTLA-4 (Ipilimumab) 3 mg/kg/2 weeks</td><td>F 68</td><td>No/No</td><td>No</td><td>Yes</td><td>III/6 weeks</td><td>1/na</td><td>Negative</td><td>Negative</td><td>na</td><td>na</td><td>na</td><td>GC (na)</td><td>No</td></tr><tr><td>Park, 2018 [43]</td><td>anti-PD-1 (Pembrolizumab) 1 cycle/2 weeks</td><td>M 52</td><td>No/Yes (g)</td><td>No</td><td>Yes</td><td>III/9 weeks</td><td>na/na</td><td>na</td><td>na</td><td>na</td><td>na</td><td>na</td><td>GC (na)</td><td>No</td></tr><tr><td>Campredon, 2018 [44]</td><td>anti-PD-1 (Nivolumab) na</td><td>M 61</td><td>No/No</td><td>No</td><td>Yes</td><td>III/6 weeks</td><td>1/1</td><td>Negative</td><td>Negative</td><td>na</td><td>na</td><td>na</td><td>GC (na)</td><td>No</td></tr><tr><td>Sagiv, 2019 [42]</td><td>anti-CTLA-4 and anti-PD-1 (Ipilimumab and Nivolumab) 3 mg/kg/2 weeks</td><td>M 73</td><td>No</td><td>No</td><td>Yes</td><td>II/6 weeks</td><td>1/1</td><td>Negative</td><td>Negative</td><td>na</td><td>na</td><td>na</td><td>GC (na)</td><td>No</td></tr></tbody></table>
<table><caption>Table 3. *Cont.*</caption><thead><tr><th>First Author, Year</th><th>ICPi (Name) and Dose</th><th>Sex Age</th><th>Personal/Familial History of AID or TD</th><th>Hyper-Thyroidism</th><th>GO</th><th>Cycle/Time</th><th>FT4/FT3 (in ULN)</th><th>TRAb (ULN)</th><th>TPOAb</th><th>Iodine 99mTc Up-take</th><th>Doppler US Vascular Pattern</th><th>Other irAE</th><th>Treatment (Duration)</th><th>Hypothyroidism Evolution</th></tr></thead><tbody><tr><td>Sagiv, 2019 [42]</td><td>Graves' disease before ICPis anti-PD-1 (Nivolumab) 3 mg/kg/2 weeks</td><td>M 42</td><td>No</td><td>Yes (h)</td><td>Yes (i)</td><td>III/8 weeks</td><td>&gt;1 (na)</td><td>Positive (na)</td><td>Neg/na</td><td>na</td><td>na</td><td>na</td><td>No (j)</td><td>Yes (k)</td></tr></tbody></table>

FT3 and TRAb are expressed as number of times greater than normal. ICPi: immune checkpoint inhibitor; AID: auto-immune disease; TD: thyroid dysfunction; GO: Graves' orbitopathy; FT4: free thyroxine; FT3: free triiodothyronine; TSH: thyroid stimulating hormone; TRAb: TSH-receptor autoantibodies; TPOAb: thyroperoxidase autoantibodies; irAE: immune-related adverse event; anti-CTLA-4: anti-cytotoxic T-lymphocytic-associated antigen-4 antibodies; anti-PD-1: anti-programmed cell death 1 protein antibodies; M: male; F: female; ATD: antithyroid drug; GC: glucocorticoids; T1D: type 1 diabetes; ULN upper limit normal; na: not available. (a) Thyroidectomy was performed during surgery to ablate adjacent cancer; (b) Post-surgery; (c) Subclinical hyperthyroidism; (d) TRAb-negative after 7 months of ICPi treatment; (e) Glucocorticoids for colitis; (f) After 17 months of treatment (not available initially); (g) Two cases of hypothyroidism; (h) Diagnosis of Graves' disease without GO after Pazopanib treatment. Normalized TSH with ATD treatment but TRAb still positive. Nivolumab started 1 year after, with appearance of hyperthyroidism and GO; (i) Clinical Activity Score: 1/10 but other Thyroid Eye Disease signs; (j) Due to lack of ophthalmic inflammatory signs and symptoms; (k) TRAb still positive, whereas secondary hypothyroidism.
In our case series of ICPi-induced GD, patients with high TRAb or high FT4 at diagnosis later showed a thyroiditis-like evolution, and not all patients with TPOAb developed hypothyroidism: neither TPOAb, nor TRAb value, nor FT4 initial value seems to be predictive of classical GD or thyroiditis-like evolution.

In the literature, female gender is described as being a risk factor for ICPi-induced TD, although this is less pronounced than in spontaneous forms [7,46,47] and it is not described in all studies [11,48]. In our entire cohort of 243 patients with ICPi-induced thyrotoxicosis, males were over-represented (60%). The literature review of ICPi-induced Graves' hyperthyroidism (Table 3) shows a higher proportion of males than females in the cases previously reported (7/8), which is unexpected, because GD is usually a predominantly female condition. This was not the case in our cohort of GD (females were over-represented at 60%), likely due to the small numbers.

Clinical trials of ICPis excluded patients with pre-existing active autoimmune diseases because of concerns of a high susceptibility to severe irAEs [49,50]. However, a growing body of evidence indicates that ICPis may be safe and effective in these patients [51,52]. A prospective study of 45 patients has shown that overall survival time and objective response rates did not differ between patients with a pre-existing AID and patients without a pre-existing AID when treated with anti-PD-1 antibodies. Nonetheless, a pre-existing AID was associated with a significantly increased risk of irAEs [53]. Although irAEs may resemble AID, their pathophysiology remains poorly understood. One important explanation may be that following immune checkpoint inhibition, T cells and other immune cells are activated, resulting in the production of pro-inflammatory cytokines which may lead to off-target inflammation and autoimmunity [51]. Among the three cases of pre-existing GD in our cohort, two were diagnosed at their regular check-up just before commencement of ICPi treatment. Our results are reassuring on their evolution when treated with ICPis, with none developing Graves' orbitopathy, severe thyrotoxicosis, nor other irAE during treatment, suggesting the safety of ICPis in this autoimmune context. Nevertheless, close monitoring of thyroid function is required because these patients may progress to secondary hypothyroidism.

Two retrospective and two prospective studies reported that positive TPOAb and/or thyroglobulin autoantibodies (TgAb) are associated with a 40 to 70% risk of hypothyroidism during treatment, and that patients who had ICPi-induced hypothyroidism had positive anti-thyroid autoantibodies in 75 to 100% of cases [54–57]. These elements suggest that ICPI-induced thyroid dysfunction may have a pathogenesis similar to spontaneous autoimmune hypothyroidism [16]. Guidelines recommend the evaluation of thyroid function before commencing ICPi treatment, with monitoring of thyroid function during the first months of treatment [15,16]. Even closer monitoring is needed if patients have pre-existing autoimmune thyroid, but systematic screening of thyroid antibodies is not recommended. Note that in the Osorio study [56], survival was better if patients developed ICPi-induced thyroid dysfunction, as suggested by others if there was an occurrence of irAEs [58–60].

Corticosteroid therapy may influence the course of ICPi-induced thyroid dysfunction [57,61]. Kimbara et al. noted that of 20 patients with induced thyrotoxicosis, five of the six who did not develop secondary hypothyroidism had received corticosteroid therapy for another reason [57]. This could also explain the evolution of our two patients who presented with induced GD showing classical evolution without hypothyroidism, because they had received corticosteroids for another irAE. A recent review of the literature is reassuring on the use of corticosteroids for irAE management, finding that it seems not to reduce overall survival in cancer patients treated with ICPis [62,63] and may be safely administered without compromising outcomes [16,64]. Conversely, a detrimental effect on survival has been suggested when used for cancer-related symptoms or for the management of a pre-existing AID, because high-dose steroids can theoretically reverse the anti-cancer benefit of ICPi treatment [51,62].

ICPi-induced thyrotoxicosis, when moderate, is usually controlled with symptomatic treatment. ESMO guidelines recommend temporarily suspending ICPi treatment in the case
of severe thyrotoxicosis, which necessitates treatment with corticosteroids or ATD [16]. ICPi treatment can be re-initiated later with the agreement of the oncologist, and thyrotoxicosis should not be a reason for the definitive cessation of ICPis. The presence of an ICPi-induced endocrinopathy must not contraindicate the use of another anti-cancer therapy, including those of the same class [15]. In severe Graves' orbitopathy, ICPis should be stopped in the case of sight-threatening prognosis. Published French guidelines recommend that the use of ATD should be reserved for hyperthyroidism with TRAb positivity or high iodine uptake on scintigraphy proving a primary thyroid pathology [15]. In the case of thyroiditis, ATD is ineffective because of the cytolytic mechanism underlying thyrotoxicosis. Our study shows that despite TRAb positivity, ATD is not always required because about one-half of the patients will spontaneously evolve towards hypothyroidism.

**5. Conclusions**

ICPi-induced Graves' disease is very rare and represents about 2% of ICPi-induced thyrotoxicosis, although it is likely that this rate will be increased with the use of combinations of ICPis. TRAb-positivity is not predictive of the evolution of hyperthyroidism, and patients may show evolution similar to classic Graves' disease, with long antithyroid drug therapy, or may present a classic pattern of thyroiditis which rapidly evolves to hypothyroidism. Evaluation of pre-therapeutic thyroid function is necessary to identify at-risk populations, and biochemical follow-up is recommended throughout ICPi treatment to facilitate the early diagnosis of thyroid dysfunction, particularly because the clinical signs are very non-specific in this neoplastic context. Testing for TRAb-positivity should be widely prescribed, especially in the absence of a rapid improvement of thyroid function. If patients are TRAb-positive, our work would favor carrying out thyroid scintigraphy to discriminate between patients whose thyrotoxicosis will quickly resolve and those who will require specific treatment. ICPi treatment in patients with pre-existing GD showed no exacerbation as a result of treatment and did not develop irAE. Lastly, GD should not be a contra-indication for ICPi treatment, subject to close biochemical monitoring and awareness of the risk of evolution toward hypothyroidism.

**Author Contributions:** Conceptualization, M.P., J.A.-d.P. and F.B.-C.; Methodology, M.P., J.A.-d.P. and F.B.-C.; Validation, M.P., J.A.-d.P. and F.B.-C.; Formal Analysis, M.P.; Investigation, J.A.-d.P. and C.C.-A.; Data Curation, M.P.; Writing—Original Draft Preparation, M.P.; Writing—Review and Editing, J.A.-d.P., F.B.-C., C.C.-A., G.R., S.D., K.C., S.A. and E.D.; Visualization, M.P.; Supervision, J.A.-d.P. and F.B.-C. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board (Commission Nationale Informatique et Liberté; no. 18-297) and Ethics Committee (no. 19-163, 14.02.2019) of HOSPICES CIVILS DE LYON.

**Informed Consent Statement:** Informed consent was obtained from all living subjects involved in the study.

**Data Availability Statement:** The data presented in this study are available in the manuscript. Complementary data are available on request from the corresponding author.

**Acknowledgments:** We acknowledge Editingbiomed.com for manuscript editing and correction, and all of the clinicians who referred patients included in the study.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Vaddepally, R.K.; Kharel, P.; Pandey, R.; Garje, R.; Chandra, P.A. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. *Cancers* **2020**, *12*, 738. [CrossRef]

2. Arnaud-Coffin, P.; Maillet, D.; Gan, H.K.; Stelmes, J.-J.; You, B.; Dalle, S.; Péron, J. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. *Int. J. Cancer* **2019**, *145*, 639–648. [CrossRef] [PubMed]
3. Torino, F.; Corsello, S.M.; Salvatori, R. Endocrinological side-effects of immune checkpoint inhibitors. *Curr. Opin. Oncol.* **2016**, *28*, 278–287. [CrossRef] [PubMed]

4. Byun, D.J.; Wolchok, J.D.; Rosenberg, L.M.; Girotra, M. Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies. *Nat. Rev. Endocrinol.* **2017**, *13*, 195–207. [CrossRef] [PubMed]

5. De Filette, J.; Andreescu, C.E.; Cools, F.; Bravenboer, B.; Velkeniers, B. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. *Horm. Metab. Res.* **2019**, *51*, 145–156. [CrossRef]

6. Barroso-Sousa, R.; Barry, W.T.; Garrido-Castro, A.C.; Hodi, F.S.; Min, L.; Krop, I.E.; Tolaney, S.M. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens. *JAMA Oncol.* **2018**, *4*, 173–182. [CrossRef]

7. Morganstein, D.; Lai, Z.; Spain, L.; Diem, S.; Levine, D.; Mace, C.; Gore, M.; Larkin, J. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. *Clin. Endocrinol.* **2017**, *86*, 614–620. [CrossRef]

8. Shang, Y.H.; Zhang, Y.; Li, J.H.; Li, P.; Zhang, X. Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: A systematic review and meta-analysis. *Immunotherapy.* **2017**, *9*, 261–272. [CrossRef]

9. Anceau, C.C.; Abeillon, J.; Maillet, D.; Borson-Chazot, F.; Disse, E. Les dysthyroïdies sous immunothérapie anti-cancéreuse. *Bull. Cancer* **2020**, *107*, 262–271. [CrossRef]

10. Chang, L.-S.; Barroso-Sousa, R.; Tolaney, S.M.; Hodi, F.S.; Kaiser, U.B.; Min, L. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. *Endocr. Rev.* **2019**, *40*, 17–65. [CrossRef]

11. Patel, N.S.; Oury, A.; Daniels, G.A.; Bazhenova, L.; Patel, S.P. Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment. *Oncologist.* **2018**, *23*, 1236–1241. [CrossRef]

12. Joshi, M.N.; Whitelaw, B.C.; Palomar, M.T.P.; Wu, Y.; Carroll, P.V. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: Clinical review. *Clin. Endocrinol.* **2016**, *85*, 331–339. [CrossRef]

13. Barroso-Sousa, R.; Ott, P.A.; Hodi, F.S.; Kaiser, U.B.; Tolaney, S.M.; Min, L. Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management. *Cancer* **2018**, *124*, 1111–1121. [CrossRef]

14. Eggermont, A.M.M.; Chiarion-Sileni, V.; Grob, J.-J.; Dummer, R.; Wolchok, J.D.; Schmidt, H.; Hamid, O.; Robert, C.; Ascierto, P.A.; Richards, J.M.; et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial. *Lancet Oncol.* **2015**, *16*, 522–530. [CrossRef]

15. Castinetti, F.; Albarel, F.; Archambeaud, F.; Bertherat, J.; Bouillet, B.; Buffier, P.; Briet, C.; Cariou, B.; Caron, P.; Chabre, O.; et al. French Endocrine Society Guidance on endocrine side effects of immunotherapy. *Endocr.-Related Cancer* **2018**, *26*, G1–G18. [CrossRef] [PubMed]

16. Haanen, J.; Carbonnel, F.; Robert, C.; Kerr, K.; Peters, S.; Larkin, J.; Jordan, K. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **2017**, *28*, iv119–iv142. [CrossRef] [PubMed]

17. Lee, H.; Hodi, F.S.; Giobbie-Hurder, A.; Ott, P.A.; Buchbinder, E.I.; Haq, R.; Tolaney, S.; Barroso-Sousa, R.; Zhang, K.; Donahue, H.; et al. Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy. *Cancer Immunol. Res.* **2017**, *5*, 1133–1140. [CrossRef] [PubMed]

18. Delivanis, D.A.; Gustafson, P.M.P.; Bornschlegl, S.; Merten, A.M.M.; Kottschade, A.L.; Withers, S.; Dietz, P.A.B.; Ryder, M. Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. *J. Clin. Endocrinol. Metab.* **2017**, *102*, 2770–2780. [CrossRef] [PubMed]

19. De Filette, J.; Jansen, Y.; Schreuer, M.; Everaert, H.; Velkeniers, B.; Neyns, B.; Bravenboer, B. Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab. *J. Clin. Endocrinol. Metab.* **2016**, *101*, 4431–4439. [CrossRef]

20. Levy, M.; Abeillon, J.; Dalle, S.; Assaad, S.; Borson-Chazot, F.; Disse, E.; Raverot, G.; Cugnet-Anceau, C. Anti-PD1 and Anti-PDL1-Induced Hypophysitis: A Cohort Study of 17 Patients with Longitudinal Follow-Up. *J. Clin. Med.* **2020**, *9*, 3280. [CrossRef] [PubMed]

21. Goichot, B.; Leenhardt, L.; Massart, C.; Raverot, V.; Tramalloni, J.; Iraqi, H. Diagnostic procedure in suspected Graves' disease. *Ann. d'Endocrinologie* **2018**, *79*, 608–617. [CrossRef]

22. Bartalena, L.; Baldeschi, L.; Boboridis, K.; Eckstein, A.; Kahaly, G.J.; Marcocci, C.; Perros, P.; Salvi, M.; Wiersinga, W.M.; on behalf of the European Group on Graves" Orbitopathy (EUGOGO). The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. *Eur. Thyroid. J.* **2016**, *5*, 9–26. [CrossRef] [PubMed]

23. Lazarus, J.H. Epidemiology of Graves' orbitopathy (GO) and relationship with thyroid disease. *Best Pr. Res. Clin. Endocrinol. Metab.* **2012**, *26*, 273–279. [CrossRef] [PubMed]

24. Antonelli, A.; Fallahi, P.; Elia, G.; Ragusa, F.; Paparo, S.R.; Ruffilli, I.; Patrizio, A.; Gonnella, D.; Giusti, C.; Virili, C.; et al. Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. *Best Pr. Res. Clin. Endocrinol. Metab.* **2020**, *34*, 101388. [CrossRef] [PubMed]

25. Bahn, R.S. Autoimmunity and Graves' disease. *Clin. Pharmacol. Ther.* **2012**, *91*, 577–579. [CrossRef] [PubMed]

26. Torimoto, K.; Okada, Y.; Nakayamada, S.; Kubo, S.; Tanaka, Y. Anti-PD-1 Antibody Therapy Induces Hashimoto's Disease with an Increase in Peripheral Blood Follicular Helper T Cells. *Thyroid.* **2017**, *27*, 1335–1336. [CrossRef]

27. Angell, T.E.; Min, L.; Wieczorek, T.J.; Hodi, F.S. Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma. *Genes Dis.* **2018**, *5*, 46–48. [CrossRef]
28. Daniels, G.H.; Vladić, A.; Brinar, V.; Zavalishin, I.; Valente, W.; Oyuela, P.; Palmer, J.; Margolin, D.H. Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients With Relapsing-Remitting Multiple Sclerosis. *J. Clin. Endocrinol. Metab.* **2014**, *99*, 80–89. [CrossRef] [PubMed]

29. McElnea, E.; Mhéalóid, Á.N.; Moran, S.; Kelly, R.; Fulcher, T. Thyroid-Like Ophthalmopathy in a Euthyroid Patient Receiving Ipilimumab. *Orbit* **2014**, *33*, 424–427. [CrossRef] [PubMed]

30. Min, L.; Vaidya, A.; Becker, C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. *Eur. J. Endocrinol.* **2011**, *164*, 303–307. [CrossRef]

31. Borodic, G.; Hinkle, D.M.; Cia, Y. Drug-Induced Graves Disease From CTLA-4 Receptor Suppression. *Ophthalmic Plast. Reconstr. Surg.* **2011**, *27*, e87–e88. [CrossRef] [PubMed]

32. Ni, J.; Qiu, L.-J.; Zhang, M.; Wen, P.-F.; Ye, X.-R.; Liang, Y.; Pan, H.-F.; Ye, N.-Q. CTLA-4 CT60(rs3087243) polymorphism and autoimmune thyroid diseases susceptibility: A comprehensive meta-analysis. *Endocr. Res.* **2014**, *39*, 180–188. [CrossRef]

33. Vaidya, B.; Kendall-Taylor, P.; Pearce, S.H.S. The Genetics of Autoimmune Thyroid Disease. *J. Clin. Endocrinol. Metab.* **2002**, *87*, 5385–5397. [CrossRef]

34. Ueda, H.; Howson, J.M.; Esposito, L.; Heward, J.; Chamberlain, G.; Rainbow, D.B.; Hunter, K.M.; Smith, A.N.; Di Genova, G.; Herr, M. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. *Nature* **2003**, *423*, 506–511. [CrossRef]

35. Azmat, U.; Liebner, D.; Joehlin-Price, A.; Agrawal, A.; Nabhan, F. Treatment of Ipilimumab Induced Graves' Disease in a Patient with Metastatic Melanoma. *Case Rep Endocrinol.* **2016**, *2016*, 1–4. [CrossRef]

36. Gan, E.H.; Mitchell, A.L.; Plummer, R.; Pearce, S.; Perros, P. Tremelimumab-Induced Graves Hyperthyroidism. *Eur. Thyroid. J.* **2017**, *6*, 167–170. [CrossRef]

37. Brancatella, A.; Viola, N.; Brogioni, S.; Montanelli, L.; Sardella, C.; Vitti, P.; Marcocci, C.; Lupi, I.; Latrofa, F. Graves' Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature. *Eur. Thyroid. J.* **2019**, *8*, 192–195. [CrossRef]

38. Yajima, K.; Akise, Y. A Case Report of Graves' Disease Induced by the Anti-Human Programmed Cell Death-1 Monoclonal Antibody Pembrolizumab in a Bladder Cancer Patient. *Case Rep. Endocrinol.* **2019**, *2019*, 1–5. [CrossRef] [PubMed]

39. Iadarola, C.; Croce, L.; Quaquarini, E.; Teragni, C.; Pinto, S.; Bernardo, A.; Fonte, R.; Marinò, M.; Rotondi, M.; Chiovato, L. Nivolumab Induced Thyroid Dysfunction: Unusual Clinical Presentation and Challenging Diagnosis. *Front. Endocrinol.* **2019**, *9*, 813. [CrossRef] [PubMed]

40. Yamada, H.; Okajima, F.; Onda, T.; Fujimori, S.; Emoto, N.; Sugihara, H. New-onset graves' disease after the initiation of nivolumab therapy for gastric cancer: A case report. *BMC Endocr. Disord.* **2020**, *20*, 1–6. [CrossRef] [PubMed]

41. Kurihara, S.; Oikawa, Y.; Nakajima, R.; Satomura, A.; Tanaka, R.; Kagamu, H.; Shimada, A. Simultaneous development of Graves' disease and type 1 diabetes during anti-programmed cell death-1 therapy: A case report. *J. Diabetes Investig.* **2020**, *11*, 1006–1009. [CrossRef]

42. Sagiv, O.; Kandl, T.J.; Thakar, S.D.; Thuro, B.A.; Busaidy, N.L.; Cabanillas, M.; Jimenez, C.; Dadu, R.; Graham, P.H.; Debnam, J.M.; et al. Extraocular Muscle Enlargement and Thyroid Eye Disease-like Orbital Inflammation Associated with Immune Checkpoint Inhibitor Therapy in Cancer Patients. *Ophthalmic Plast. Reconstr. Surg.* **2019**, *35*, 50–52. [CrossRef]

43. Park, E.S.; Rabinowits, G.; Hamnvik, O.-P.R.; Dagi, L.R. A case of Graves' ophthalmopathy associated with pembrolizumab (Keytruda) therapy. *J. Am. Assoc. Pediatr. Ophthalmol. Strabismus* **2018**, *22*, 310–312. [CrossRef] [PubMed]

44. Campredon, P.; Imbert, P.; Mouly, C.; Grunenwald, S.; Mazières, J.; Caron, P. Severe Inflammatory Ophthalmopathy in a Euthyroid Patient during Nivolumab Treatment. *Eur. Thyroid. J.* **2018**, *7*, 84–87. [CrossRef] [PubMed]

45. Dalvin, L.A.; Shields, C.L.; Orloff, M.; Sato, T.; Shields, J.A. CHECKPOINT INHIBITOR IMMUNE THERAPY. *Retin.* **2018**, *38*, 1063–1078. [CrossRef] [PubMed]

46. Ryder, M.; Callahan, M.; Postow, M.A.; Wolchok, J.; Fagin, J.A. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: A comprehensive retrospective review from a single institution. *Endocrine-Related Cancer* **2014**, *21*, 371–381. [CrossRef]

47. Orlov, S.; Salari, F.; Kashat, L.; Walfish, P.G. Induction of Painless Thyroiditis in Patients Receiving Programmed Death 1 Receptor Immunotherapy for Metastatic Malignancies. *J. Clin. Endocrinol. Metab.* **2015**, *100*, 1738–1741. [CrossRef] [PubMed]

48. Yamazaki, H.; Iwasaki, H.; Yamashita, T.; Yoshida, T.; Suganuma, N.; Yamanaka, T.; Masudo, K.; Nakayama, H.; Kohagura, K.; Rino, Y.; et al. Potential Risk Factors for Nivolumab-induced Thyroid Dysfunction. *Vivo* **2017**, *31*, 1225–1228. [CrossRef]

49. Hodi, F.S.; O'Day, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J.C.; et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. *N. Engl. J. Med.* **2010**, *363*, 711–723. [CrossRef]

50. Robert, C.; Schachter, J.; Long, G.V.; Arance, A.; Grob, J.J.; Mortier, L.; Daud, A.; Carlino, M.S.; McNeil, C.; Lotem, M.; et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. *N. Engl. J. Med.* **2015**, *372*, 2521–2532. [CrossRef]

51. Haanen, J.; Ernstoff, M.; Wang, Y.; Menzies, A.; Puzanov, I.; Grivas, P.; Larkin, J.; Peters, S.; Thompson, J.; Obeid, M. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy. *Ann. Oncol.* **2020**, *31*, 724–744. [CrossRef] [PubMed]

52. Abdel-Wahab, N.; Shah, M.; Lopez-Olivo, M.A.; Suarez-Almazor, M.E. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease. *Ann. Intern. Med.* **2018**, *168*, 121–130. [CrossRef] [PubMed]
53. Danlos, F.-X.; Voisin, A.-L.; Dyevre, V.; Michot, J.-M.; Routier, E.; Taillade, L.; Champiat, S.; Aspeslagh, S.; Haroche, J.; Albiges, L.; et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. *Eur. J. Cancer* **2018**, *91*, 21–29. [CrossRef] [PubMed]

54. Kobayashi, T.; Iwama, S.; Yasuda, Y.; Okada, N.; Tsunekawa, T.; Onoue, T.; Takagi, H.; Hagiwara, D.; Ito, Y.; Morishita, Y.; et al. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study. *J. Endocr. Soc.* **2018**, *2*, 241–251. [CrossRef]

55. Maekura, T.; Naito, M.; Tahara, M.; Ikegami, N.; Kimura, Y.; Sonobe, S.; Kobayashi, T.; Tsuji, T.; Minomo, S.; Tamiya, A.; et al. Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer. *Vivo* **2018**, *31*, 1035–1039. [CrossRef]

56. Osorio, J.C.; Ni, A.; Chait, J.E.; Pollina, R.; Kasler, M.K.; Stephens, D.; Rodriguez, C.; Cambridge, L.; Rizvi, H.; Wolchok, J.D.; et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. *Ann. Oncol.* **2017**, *28*, 583–589. [CrossRef]

57. Kimbara, S.; Fujiwara, Y.; Iwama, S.; Ohashi, K.; Kuchiba, A.; Arima, H.; Yamazaki, N.; Kitano, S.; Yamamoto, N.; Ohe, Y. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. *Cancer Sci.* **2018**, *109*, 3583–3590. [CrossRef]

58. Haratani, K.; Hayashi, H.; Chiba, Y.; Kudo, K.; Yonesaka, K.; Kato, R.; Kaneda, H.; Hasegawa, Y.; Tanaka, K.; Takeda, M.; et al. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. *JAMA Oncol.* **2018**, *4*, 374–378. [CrossRef]

59. Weber, J.S.; Hodi, F.S.; Wolchok, J.D.; Topalian, S.L.; Schadendorf, D.; Larkin, J.; Sznol, M.; Long, G.V.; Li, H.; Waxman, I.M.; et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. *J. Clin. Oncol.* **2017**, *35*, 785–792. [CrossRef]

60. Freeman-Keller, M.; Kim, Y.; Cronin, H.; Richards, A.; Gibney, G.T.; Weber, J.S. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. *Clin. Cancer Res.* **2016**, *22*, 886–894. [CrossRef]

61. Yamauchi, I.; Sakane, Y.; Fukuda, Y.; Fujii, T.; Taura, D.; Hirata, M.; Hirota, K.; Ueda, Y.; Kanai, Y.; Yamashita, Y.; et al. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study. *Thyroid.* **2017**, *27*, 894–901. [CrossRef] [PubMed]

62. Petrelli, F.; Signorelli, D.; Ghidini, M.; Ghidini, A.; Pizzutilo, E.G.; Ruggieri, L.; Cabiddu, M.; Borgonovo, K.; Dognini, G.; Brighenti, M.; et al. Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. *Cancers* **2020**, *12*, 546. [CrossRef] [PubMed]

63. Ricciuti, B.; Dahlberg, S.E.; Adeni, A.; Sholl, L.M.; Nishino, M.; Awad, M.M. Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. *J. Clin. Oncol.* **2019**, *37*, 1927–1934. [CrossRef] [PubMed]

64. Brahmer, J.R.; Lacchetti, C.; Schneider, B.J.; Atkins, M.B.; Brassil, K.J.; Caterino, J.M.; Chau, I.; Ernstoff, M.S.; Gardner, J.M.; Ginex, P.; et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. *J. Clin. Oncol. Am. Soc. Clin. Oncol. J.* **2018**, *36*, 1714–1768. [CrossRef]